June 18, 2015
Chloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco talks with Axel Grothey, MD, of the Mayo Clinic about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic colorectal cancer. (Abstracts 103 and 3511)
May 18, 2015
#Zulekhahospital launched #SmearDontFear - Cervical Cancer Awareness Campaign on 18 May 2015
March 14, 2015
Rejuvenation Biotechnology 2014 Cancer Session (from August 22, 2014, 1:00pm) “Accelerating Knowledge Turns: The I-SPY Model and Drug Development” Presenter: Laura Esserman, Professor, Departments of Surgery and Radiology, and Affiliate Faculty, Institute for Health Policy Studies and Director, Carol Franc Buck Breast Care Center; Co-Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.
December 10, 2014
During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Thomas Martin from the UCSF Medical Center joined Patient Power to share encouraging multiple myeloma news coming out of the meeting. He discussed the latest results from a study combining a novel myeloma therapy with lenalidomide (Revlimid®) and dexamethasone as well as the promise of CD-38 antibodies, which he referred to as “blockbuster drugs.” Dr. Martin stressed the important of clinical trials related to FDA approval and why all patients should know about the many trials available in a number of patient populations across the country.
September 7, 2014
"Cognitive Orientation and Meaning as Predictors of Health and Disease in Cancer Patients: Lessons Learned from 30 years of Psycho-oncology Research and Practice in Israel" with Shulamith Kreitler PhD, Professor Emeritus, Department of Psychology, Tel Aviv University; Director of Psychooncology Research Center, Sheba Medical Center at Tel-Hashomer, Israel
August 8, 2014
July 3, 2014
June 30, 2014
June 24, 2014
June 24, 2014